Program Content
Introduction
Hypertrophic cardiomyopathy (HCM) is a complex heterogeneous disorder characterized by hypertrophied and disorganized myocytes with varying degrees of interstitial fibrosis.1) Obstructive HCM, which accounts for two-thirds of all HCM cases, is a chronic, progressive cardiovascular condition, often undiagnosed until a significant cardiac event has occurred, and can pose a diagnostic challenge to even the most experienced non-specialist healthcare professionals (HCPs).2) HCM has an estimated prevalence of 1:500, and most patients are clinically undiagnosed.2) In patients with HCM, there is a substantial unmet need with respect to the risk of complications that associates with a poorer long-term survival compared to the general population.3) The risk of some of these complications, such as sudden cardiac death, may be lowered if existing practice guidelines are followed.
Faculty
PERRY ELLIOTT, MBBS, MD, FRCP Director | UCL Institute of Cardiovascular Science London, UK
ANJALI OWENS, MD University of Pennsylvania & Penn Medicine Philadelphia, PA, USA
Educational needs and learning objectives
The goal of this activity is to increase HCPs’ knowledge and competency in evidence-based diagnosis and treatment strategies for patients with obstructive HCM.
Learning Objectives
- After completing this activity, participants should be able to:
- Explain the pathophysiology of obstructive HCM and mechanisms accounting for its signs and symptoms;
- Identify clinical presentations of obstructive HCM and patients for subsequent investigations, including genetic screening;
- List differential diagnoses for HCM and clinically validated diagnostic tests to establish the correct diagnosis;
- Apply recommendations for the diagnosis and management of HCM, such as the 2020 AHA/ACC guidelines and the 2014 ESC guidelines;
- Outline the indications for available medical treatment and invasive procedures;
- Select appropriate management plans after considering patient characteristics, clinical factors, and the safety and efficacy of available therapeutic agents;
- Summarize the available clinical data for novel agents such as mavacamten.
Target Audience
This activity is intended for HCPs who manage adult patients with HCM, including Cardiologists, Internal Medicine specialists, Primary Care Physicians, and allied healthcare professionals practicing globally (inclusive of USA).
Enduring Materials CE Activity
Release Date: February 23, 2023
Expiration Date: February 23, 2024
This activity has passed its expiration date.
Disclosures
Speakers disclosures
Professor Perry Elliott, MBBS, MD, FRCP
Prof. Elliott has disclosed the following financial relationships:
Advisory board: BMS, Novo Nordisk, Pfizer, Sarepta
Consulting: Biomarin, BMS, Novo Nordisk, Pfizer, Sarepta
Lecture fees: Pfizer
CME Reviewer
Sandy Mardant, Oakstone Publishing – Director of Continuing Education
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relationships with ineligible companies.
Peer Reviewer
This activity has been peer-reviewed and the reviewer has disclosed no financial relationships.
Editor
Rita Aresta MD
Scientific Content Manager, SEI Healthcare
Rita Aresta MD has disclosed no financial relationships.
Dr. Anjali Owens, MD; Associate Professor of Medicine
Dr. Owens has disclosed the following financial relationships:
Consultant: Edgewise Therapeutics, Pfizer, Renovacor, Tenaya.
Steering committee, site PI, consultant: Bristol Myers Squibb, Cytokinetics.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and SEI Healthcare LLC. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
Oakstone Publishing designates this live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Expiration Dates
Upon completion of this activity, the deadline to complete the evaluation form to obtain CME credits is February 23, 2024.
Commercial Support
This activity has been developed by SEI Healthcare LLC with the assistance of the faculty members, supported by an independent medical grant by Bristol Myers Squibb.
Participation Costs
There is no cost to participate in this CE activity.
CME Inquiries
For all CME policy-related inquiries, please contact us at [email protected]
How to Earn CE Credit
Physicians, Physician Assistants, Nurse Practitioners, Nurses
1.Go to the following web site: https://my-ime.com
2.Register or enter your profile ID.
3.Complete the activity. Your CE records will be electronically sent to your email account.
References:
1) Hutt E et al. Future Cardiol. 2021;17(7):1261–1267.
2) Butzner M et al. Front Cardiovasc Med. 2022;8:765876.
3) Pujades-Rodriguez M et al. PLoS One. 2018;13(1):e0191214.
